|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
I'll be on the ground at the FT's US Pharma and Biotech Summit next Thursday, moderating some fascinating conversations about the ways consumers are influencing how healthcare is delivered. One other session I'm looking forward to: A senior FDA official will be onstage. Check out the agenda here. |
|
|
|
Lydia Ramsey Pflanzer |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
Amazon’s One Medical clinic's in-person prescription pickup machine. (Credit: Amazon Pharmacy) |
|
|
|
by Nicole DeFeudis
|
The Ozempic pill is coming to Amazon Pharmacy’s prescription drug kiosks. It’s an expansion for the kiosks, which operate like vending machines and have been... | |
|
|
|
|
|
|
by Max Gelman
|
There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase... | |
|
|
|
|
|
|
by Lei Lei Wu
|
EnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects. The... | |
|
|
|
|
|
|
by Ayisha Sharma
|
Angelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases. The buyout will add three... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reportedinitial data in six patients who received the low
dose... | |
|
|
|
|
|
